SEC FIlings

09 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 9, 2023
Posted by Ulisses

09 Jan

SEC FIlings

Current Report

January 9, 2023
Posted by Ulisses

03 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 6, 2023
Posted by Ulisses

03 Jan

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 6, 2023
Posted by Ulisses

03 Jan

SEC FIlings

Current Report

January 3, 2023
Posted by Jitendra

27 Dec

SEC FIlings

Notice of Effectiveness

January 3, 2023
Posted by Ulisses

27 Dec

SEC FIlings

Prospectus [Rule 424(b)(3)]

January 3, 2023
Posted by Ulisses

20 Dec

SEC FIlings

Securities and Exchange Commission

December 21, 2022
Posted by Ulisses

09 Dec

SEC FIlings

Notice of Effectiveness

December 14, 2022
Posted by Jitendra

09 Dec

SEC FIlings

Prospectus [Rule 424(b)(3)]

December 12, 2022
Posted by Jitendra

Prospectus [Rule 424(b)(3)]

Current Report

Prospectus [Rule 424(b)(3)]

Prospectus [Rule 424(b)(3)]

Current Report

Notice of Effectiveness

Prospectus [Rule 424(b)(3)]

Securities and Exchange Commission

Notice of Effectiveness

Prospectus [Rule 424(b)(3)]

Gloperba Launch – Nasdaq-2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

Gout Awareness Day – May 22

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis

Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch